Bone Loss in Diabetes: Use of Antidiabetic Thiazolidinediones and Secondary Osteoporosis

نویسندگان

چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Bone Loss in Diabetes: Use of Antidiabetic Thiazolidinediones and Secondary Osteoporosis

Clinical evidence indicates that bone status is affected in patients with type 2 diabetes mellitus (T2DM). Regardless of normal or even high bone mineral density, T2DM patients have increased risk of fractures. One class of antidiabetic drugs, thiazolidinediones (TZDs), causes bone loss and further increases facture risk, placing TZDs in the category of drugs causing secondary osteoporosis. Ris...

متن کامل

Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis

BACKGROUND Rosiglitazone and pioglitazone are high-affinity peroxisome proliferator-activated receptor (PPAR)-gamma agonists with potent anti-diabetic properties and potential anti-inflammatory effects. We compared the ability of a range of oral doses of these thiazolidinediones, including those sufficient to restore insulin sensitization, to inhibit the pathogenesis of adjuvant-induced arthrit...

متن کامل

Thiazolidinediones: antidiabetic drugs with cardiovascular effects.

cardiovascular morbidity and mortality at least four times higher compared to patients without diabetes. Moreover, it is well established nowadays that the cardiovascular risk of diabetic patients without a history of a prior myocardial infarction is similar to the risk of nondiabetic patients who have already had one. Hence, the reduction of cardiovascular risk in type 2 diabetic patients usin...

متن کامل

Thiazolidinediones and bone fractures

The topic of increased risk of bone fracture associated with thiazolidinediones (TZD) treatment first drew international attention when a higher rate of fractures in women with diabetes treated with rosiglitazone was reported in the A Diabetes Outcome Program Trial (ADOPT). Subsequently, a number of clinical trials and observational studies addressing this issue have been reported and most of t...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Current Osteoporosis Reports

سال: 2010

ISSN: 1544-1873,1544-2241

DOI: 10.1007/s11914-010-0027-y